Peripheral T-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Peripheral T-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-02-24Clinical Trial Update: A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies [Phase 1]
Phase 1 clinical trial update for BP1002 in advanced lymphoid malignancies across several B-cell and T-cell lymphomas; trial status is activ…
-
CLINICAL_TRIALS research · 2025-02-19Clinical Trial Update: Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma [Phase 2]
A Phase 2 clinical trial combining chidamide with duvelisib for relapsed or refractory peripheral T-cell lymphoma is currently recruiting.
-
CLINICAL_TRIALS research · 2025-01-03Clinical Trial Update: Chidamide Plus Golidocitinib in Relapsed/Refractory Peripheral T-Cell Lymphoma [Phase 1, Phase 2]
Clinical trial update on chidamide plus golidocitinib for relapsed/refractory peripheral T-cell lymphoma, spanning Phase 1 and Phase 2; curr…
-
CLINICAL_TRIALS research · 2024-12-30Clinical Trial Update: Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma [Phase 2]
A Phase 2 clinical trial is evaluating the CAMP regimen—chidamide in combination with azacitidine, liposomal mitoxantrone, and prednisone—fo…
-
CLINICAL_TRIALS research · 2024-12-18Clinical Trial Update: Golidocitinib Plus CHOP in Newly Diagnosed PTCL [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating golidocitinib plus CHOP for newly diagnosed peripheral T-cell lymphoma is currently recruiting.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2024-12-13Clinical Trial Update: A Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) [Phase 1, Phase 2]
GFH009 is being studied as a single-agent therapy in relapsed or refractory Peripheral T-cell Lymphoma, with Phase 1/2 trials currently recr…
-
CLINICAL_TRIALS research · 2024-12-02Clinical Trial Update: Linperlisib Combined With EZH2 Inhibitor in Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL) [Phase 1]
Phase 1 trial evaluating linperlisib in combination with an EZH2 inhibitor for relapsed/refractory peripheral T-cell lymphoma; the study is …
-
CLINICAL_TRIALS research · 2024-11-25Clinical Trial Update: To Evaluate XNW5004 Tablets in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma [Phase 2]
A Phase 2 clinical trial to evaluate XNW5004 tablets in relapsed or refractory peripheral T-cell lymphoma has not yet begun recruiting.
-
CLINICAL_TRIALS trial_result · 2024-11-13Clinical Trial Update: A Study to Evaluate Activity, Safety and Tolerability of ZX-101A in Relapsed/Refractory Hematological Malignancies [Phase 1, Phase 2]
Update on the completed Phase 1/2 study of ZX-101A assessing activity, safety, and tolerability in relapsed/refractory hematological maligna…
-
CLINICAL_TRIALS research · 2024-11-12Clinical Trial Update: Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells [Phase 1, Phase 2]
An ongoing Phase 1/2 clinical trial evaluating sequential CD5/CD7-specific CAR-T cells for CD5/CD7-positive T-cell malignancies including T-…
-
CLINICAL_TRIALS research · 2024-11-06Clinical Trial Update: Pralatrexate Combined With Chidamide Bridging Allogeneic HSCT for Refractory/Relapsed Peripheral T-cell Lymphoma [NA]
This clinical trial investigates pralatrexate in combination with chidamide as a bridging therapy to allogeneic stem cell transplantation fo…
-
CLINICAL_TRIALS trial_result · 2024-10-29Clinical Trial Update: Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas [Phase 1, Phase 2]
Phase 1/2 trial updates show results for nivolumab plus standard-of-care chemotherapy in patients with Peripheral T-cell lymphoma, with the …
-
CLINICAL_TRIALS research · 2024-10-29Clinical Trial Update: Azacytidine Plus CAOLD Regimen in Relapsed/Refractory Peripheral T-Cell Lymphomas [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating azacitidine plus the CAOLD regimen in relapsed or refractory Peripheral T-cell lymphoma; currently recru…
-
CLINICAL_TRIALS research · 2024-10-08Clinical Trial Update: A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell Lymphoma [NA]
This clinical trial update describes a pilot study using a microdevice to screen candidate drugs in cutaneous lesions from patients with cut…
-
CLINICAL_TRIALS trial_result · 2024-09-27Clinical Trial Update: Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory CD30-positive Peripheral T Cell Lymphoma or Pediatric Hodgkin Lymphoma"
This Clinical Trial Update reports results from a Special Drug Use Surveillance study of Brentuximab Vedotin IV in relapsed or refractory CD…
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) [Phase 2]
Phase 2 trial evaluating oral HBI-8000 in relapsed or refractory Peripheral T-Cell Lymphoma has completed, with efficacy and safety results …
-
CLINICAL_TRIALS research · 2024-08-29Clinical Trial Update: A Clinical Study Assessing the Efficacy of Chidamide for CD30-positive Peripheral T-cell Lymphoma (PTCL). [Phase 2]
A Phase 2 clinical trial assessing the efficacy of chidamide for CD30-positive peripheral T-cell lymphoma. The trial is currently active but…
-
CLINICAL_TRIALS trial_result · 2024-08-28Clinical Trial Update: AZD4573 as Monotherapy or in Combinations With Anti-cancer Agents in Patients With r/r PTCL or r/r cHL [Phase 2]
Phase 2 trial evaluating AZD4573 as monotherapy or in combination for relapsed/refractory peripheral T-cell lymphoma and relapsed/refractory…
-
CLINICAL_TRIALS trial_result · 2024-08-27Clinical Trial Update: Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas [Phase 1, Phase 2]
This clinical trial update covers a Phase 1/2 study of pembrolizumab plus pralatrexate in relapsed or refractory peripheral T-cell lymphomas…
-
CLINICAL_TRIALS research · 2024-08-12Clinical Trial Update: A Phase II/III Study of Linperlisib Plus CHOP Versus CHOP in Patients With Newly Diagnosed Peripheral T Cell Lymphoma [Phase 2, Phase 3]
Clinical trial update for a Phase II/III study of Linperlisib plus CHOP versus CHOP in newly diagnosed peripheral T-cell lymphoma, currently…
-
CLINICAL_TRIALS research · 2024-08-07Clinical Trial Update: Phase I/IIa Study of BR1733 in Subjects With Advanced Cancers [Phase 1, Phase 2]
Phase I/IIa clinical trial update for BR1733 in advanced cancers, including follicular lymphoma, peripheral T-cell lymphoma, and diffuse lar…
-
CLINICAL_TRIALS research · 2024-08-01Clinical Trial Update: Allo-PBSCT as the First-line Treatment for Patients With the High-risk PTCL [NA]
A clinical trial is evaluating allogeneic peripheral blood stem cell transplantation as first-line therapy for high-risk peripheral T-cell l…
-
CLINICAL_TRIALS research · 2024-08-01Clinical Trial Update: RIC With Thiotepa Combined With Bu/Flu/Ara-C in Allo-HSCT for Relapsed or Refractory PTCL. [Phase 2]
A Phase 2 trial assessing reduced-intensity conditioning with thiotepa plus busulfan/fludarabine/cytarabine in allogeneic HSCT for relapsed …
-
CLINICAL_TRIALS trial_result · 2024-07-22Clinical Trial Update: Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01) [Phase 2]
Daiichi Sankyo reported an update on valemetostat tosylate (DS-3201b), an EZH1/2 dual inhibitor, in a Phase 2 trial (VALENTINE-PTCL01) for r…
-
CLINICAL_TRIALS trial_result · 2024-07-18Clinical Trial Update: Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab [Phase 2]
Phase 2 trial evaluating letermovir for prevention of cytomegalovirus reactivation in patients with hematologic malignancies treated with al…